Vise Technologies Inc. Increases Position in Boston Scientific Co. (NYSE:BSX)

Vise Technologies Inc. raised its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 106.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,170 shares of the medical equipment provider's stock after buying an additional 11,439 shares during the period. Vise Technologies Inc.'s holdings in Boston Scientific were worth $1,980,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of BSX. TFC Financial Management Inc. boosted its holdings in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Colonial Trust Co SC grew its holdings in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares in the last quarter. Valley National Advisers Inc. increased its stake in shares of Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares during the last quarter. Fairway Wealth LLC acquired a new stake in shares of Boston Scientific in the 4th quarter worth $36,000. Finally, Johnson Financial Group Inc. raised its holdings in shares of Boston Scientific by 60.1% during the 4th quarter. Johnson Financial Group Inc. now owns 469 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 176 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 1.6%

Boston Scientific stock traded down $1.65 during mid-day trading on Wednesday, hitting $104.52. The company had a trading volume of 6,362,904 shares, compared to its average volume of 6,395,933. The business has a fifty day moving average of $100.14 and a 200 day moving average of $97.61. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $154.63 billion, a price-to-earnings ratio of 83.62, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business's revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.56 earnings per share. On average, sell-side analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BSX shares. Truist Financial raised their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Needham & Company LLC reissued a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a research note on Wednesday. Piper Sandler lifted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Raymond James raised their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Stifel Nicolaus raised their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Twenty-three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $114.87.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the transaction, the executive vice president now owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. This trade represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 191,155 shares of company stock worth $19,556,047. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.